When Cancer Type Stops Mattering: The High-Stakes Bet on Tumour-Agnostic Immunotherapy
A landmark review argues that tumour-agnostic immunotherapy succeeds only when biological rationale, validated biomarkers and health-system infrastructure are aligned, using ...
